{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:45:42Z","timestamp":1794498342359,"version":"4.9.1"},"reference-count":251,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["730000F.99.1.BV10AA00006"],"award-info":[{"award-number":["730000F.99.1.BV10AA00006"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2022-304"],"award-info":[{"award-number":["075-15-2022-304"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2021-684"],"award-info":[{"award-number":["075-15-2021-684"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Members of the EGFR family of tyrosine kinase receptors are major regulators of cellular proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is associated with the development and progression of many cancer types, which makes it an attractive target for molecular-guided therapy. Two classes of EGFR-targeted cancer therapeutics include monoclonal antibodies (mAbs), which bind to the extracellular domain of EGFR, and tyrosine kinase inhibitors (TKIs), which mostly target the intracellular part of EGFR and inhibit its activity in molecular signaling. While EGFR-specific mAbs and three generations of TKIs have demonstrated clinical efficacy in various settings, molecular evolution of tumors leads to apparent and sometimes inevitable resistance to current therapeutics, which highlights the need for deeper research in this field. Here, we tried to provide a comprehensive and systematic overview of the rationale, molecular mechanisms, and clinical significance of the current EGFR-targeting drugs, highlighting potential candidate molecules in development. We summarized the underlying mechanisms of resistance and available personalized predictive approaches that may lead to improved efficacy of EGFR-targeted therapies. We also discuss recent developments and the use of specific therapeutic strategies, such as multi-targeting agents and combination therapies, for overcoming cancer resistance to EGFR-specific drugs.<\/jats:p>","DOI":"10.3390\/cells13010047","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T23:00:12Z","timestamp":1703545212000},"page":"47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-4883","authenticated-orcid":false,"given":"Nina","family":"Shaban","sequence":"first","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia"},{"name":"Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Kamashev","sequence":"additional","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia"},{"name":"Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia"},{"name":"Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Emelianova","sequence":"additional","affiliation":[{"name":"World-Class Research Center \u201cDigital Biodesign and Personalized Healthcare\u201d, Sechenov First Moscow State Medical University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Buzdin","sequence":"additional","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia"},{"name":"Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia"},{"name":"Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia"},{"name":"PathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal Growth Factor Receptor in Relation to Tumor Development: EGFR Gene and Cancer: EGFR and Cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.pharmtox.44.101802.121440","article-title":"ErbB Receptors: Directing Key Signaling Networks throughout Life","volume":"44","author":"Holbro","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"602160","DOI":"10.3389\/fgene.2021.602160","article-title":"ERBB1\/2\/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fonc.2019.01308","article-title":"Epidermal Growth Factor Receptor Family and Its Role in Gastric Cancer","volume":"9","author":"Arienti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER Family of Protein-Tyrosine Kinases and Cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB Signalling Network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 9.","DOI":"10.3390\/cancers9050052"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13353","DOI":"10.1074\/jbc.RA120.012852","article-title":"EGFR Forms Ligand-Independent Oligomers That Are Distinct from the Active State","volume":"295","author":"Byrne","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mudumbi, K.C., Burns, E.A., Schodt, D.J., Petrova, Z.O., Kiyatkin, A., Kim, L.W., Mangiacapre, E.M., Ortiz-Caraveo, I., Ortiz, H.R., and Hu, C. (2023). Distinct Interactions Stabilize EGFR Dimers and Higher-Order Oligomers in Cell Membranes. bioRxiv.","DOI":"10.1101\/2023.04.10.536273"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13307","DOI":"10.1038\/ncomms13307","article-title":"EGFR Oligomerization Organizes Kinase-Active Dimers into Competent Signalling Platforms","volume":"7","author":"Needham","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcdb.2014.03.003","article-title":"From Wavy Hair to Naked Proteins: The Role of Transforming Growth Factor Alpha in Health and Disease","volume":"28","author":"Singh","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcdb.2013.12.011","article-title":"Structure and Function of Epigen, the Last EGFR Ligand","volume":"28","author":"Schneider","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcdb.2014.01.005","article-title":"Amphiregulin","volume":"28","author":"Berasain","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1357-2725(00)00028-5","article-title":"Structure-Function and Biological Role of Betacellulin","volume":"32","author":"Dunbar","year":"2000","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1210\/me.2008-0055","article-title":"Prolactin and ErbB4\/HER4 Signaling Interact via Janus Kinase 2 to Induce Mammary Epithelial Cell Gene Expression Differentiation","volume":"22","author":"Sandahl","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0014-5793(03)01005-6","article-title":"Solution Structure of Epiregulin and the Effect of Its C-Terminal Domain for Receptor Binding Affinity","volume":"553","author":"Sato","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/107385840100700209","article-title":"Neuregulins and the Shaping of Synapses","volume":"7","author":"Ozaki","year":"2001","journal-title":"Neuroscientist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1073\/pnas.94.18.9562","article-title":"Neuregulin-3 (NRG3): A Novel Neural Tissue-Enriched Protein That Binds and Activates ErbB4","volume":"94","author":"Zhang","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/sj.onc.1202631","article-title":"Neuregulin-4: A Novel Growth Factor That Acts through the ErbB-4 Receptor Tyrosine Kinase","volume":"18","author":"Harari","year":"1999","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Henriksen, L., Grandal, M.V., Knudsen, S.L.J., van Deurs, B., and Gr\u00f8vdal, L.M. (2013). Internalization Mechanisms of the Epidermal Growth Factor Receptor after Activation with Different Ligands. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058148"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Leblanc, J.A., Sugiyama, M.G., Antonescu, C.N., and Brown, A.I. (2023). Quantitative Modeling of EGF Receptor Ligand Discrimination via Internalization Proofreading. Phys. Biol., 20.","DOI":"10.1101\/2023.05.09.539827"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/bcr1633","article-title":"HER2 Therapy. HER2 (ERBB2): Functional Diversity from Structurally Conserved Building Blocks","volume":"9","author":"Landgraf","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor\/Neuregulin and Epidermal Growth Factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature04177","article-title":"A Quantitative Protein Interaction Network for the ErbB Receptors Using Protein Microarrays","volume":"439","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21608","DOI":"10.1073\/pnas.0912101106","article-title":"Structural Analysis of the Catalytically Inactive Kinase Domain of the Human EGF Receptor 3","volume":"106","author":"Jura","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 Intracellular Domain Is Competent to Bind ATP and Catalyze Autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/MCB.01605-13","article-title":"erbB3 Is an Active Tyrosine Kinase Capable of Homo- and Heterointeractions","volume":"34","author":"Steinkamp","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.11.008","article-title":"Functional Selectivity of EGF Family Peptide Growth Factors: Implications for Cancer","volume":"122","author":"Wilson","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The Epidermal Growth Factor Receptor Variant III (EGFRvIII): Where Wild Things Are Altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/j.1349-7006.2009.01308.x","article-title":"Genetic Alterations and Signaling Pathways in the Evolution of Gliomas","volume":"100","author":"Ohgaki","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ceb.2013.11.003","article-title":"Changes in Cell and Tissue Organization in Cancer of the Breast and Colon","volume":"26","author":"Hinck","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal Growth Factor Receptor Biology in Head and Neck Cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_34","first-page":"48","article-title":"Epidermal Growth Factor Receptor (EGFR) in Lung Cancer: An Overview and Update","volume":"2","author":"Bethune","year":"2010","journal-title":"J. Thorac. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1158\/0008-5472.CAN-04-1945","article-title":"Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer","volume":"64","author":"Schraml","year":"2004","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal Growth Factor Receptor in Pancreatic Cancer","volume":"3","author":"Newman","year":"2011","journal-title":"Cancers"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5306\/wjco.v6.i5.133","article-title":"Colon Cancer and the Epidermal Growth Factor Receptor: Current Treatment Paradigms, the Importance of Diet, and the Role of Chemoprevention","volume":"6","author":"Pabla","year":"2015","journal-title":"World J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of Epidermal Growth Factor Receptor Biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pastwi\u0144ska, J., Kara\u015b, K., Karwaciak, I., and Ratajewski, M. (2022). Targeting EGFR in Melanoma\u2014The Sea of Possibilities to Overcome Drug Resistance. Biochim. Biophys. Acta (BBA)-Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2022.188754"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non\u2013Small-Cell Lung Cancer: The TORCH Randomized Trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-11-90","article-title":"High EGFR Copy Number Predicts Benefits from Tyrosine Kinase Inhibitor Treatment for Non-Small Cell Lung Cancer Patients with Wild-Type EGFR","volume":"11","author":"Wang","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","article-title":"Molecular Predictors of Outcome with Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data from the Randomized Phase III INTEREST Trial","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide Frequency of Commonly Detected EGFR Mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.21037\/tlcr-22-235","article-title":"Multiple Mutations in the EGFR Gene in Lung Cancer: A Systematic Review","volume":"11","author":"Chaves","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/COC.0000000000000282","article-title":"EGFR Exon 19 Deletion Is Associated with Favorable Overall Survival After First-Line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients","volume":"41","author":"Choi","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.31557\/APJCP.2023.24.2.709","article-title":"Mutational Damages in Malignant Lung Tumors","volume":"24","author":"Yermekova","year":"2023","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Burnett, H., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P., and Li, T. (2021). Epidemiological and Clinical Burden of EGFR Exon 20 Insertion in Advanced Non-Small Cell Lung Cancer: A Systematic Literature Review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247620"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1092587","DOI":"10.1155\/2019\/1092587","article-title":"EGFRvIII: An Oncogene with Ambiguous Role","volume":"2019","author":"Rutkowska","year":"2019","journal-title":"J. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/neuonc\/nou046","article-title":"JAK2\/STAT3 Targeted Therapy Suppresses Tumor Invasion via Disruption of the EGFRvIII\/JAK2\/STAT3 Axis and Associated Focal Adhesion in EGFRvIII-Expressing Glioblastoma","volume":"16","author":"Zheng","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal Growth Factor Receptor Mutations in Lung Cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.18632\/oncotarget.3472","article-title":"Molecular Determinants of Drug-Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer","volume":"6","author":"Tsigelny","year":"2015","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1200\/JCO.2021.39.15_suppl.8530","article-title":"Molecular Characteristics of EGFR Exon 19 Deletion Subtypes in NSCLC Patients","volume":"39","author":"Gu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_59","first-page":"e26412","article-title":"Epidermal Growth Factor Receptor Variant III Mutation, an Emerging Molecular Marker in Glioblastoma Multiforme Patients: A Single Institution Study on the Indian Population","volume":"14","author":"Garima","year":"2022","journal-title":"Cureus"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1634\/theoncologist.2019-0405","article-title":"A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib","volume":"25","author":"Li","year":"2020","journal-title":"Oncologist"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e13538","DOI":"10.1200\/JCO.2018.36.15_suppl.e13538","article-title":"Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)","volume":"36","author":"Xu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","article-title":"EGFR Fusions as Novel Therapeutic Targets in Lung Cancer","volume":"6","author":"Konduri","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.2147\/OTT.S263994","article-title":"KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma","volume":"13","author":"Xu","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the Undruggable RAS: Mission Possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of Somatic K-RAS Mutations as a Mechanism Associated with Resistance to EGFR-Targeted Agents: A Systematic Review and Meta-Analysis of Studies in Advanced Non-Small-Cell Lung Cancer and Metastatic Colorectal Cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small Molecule Inhibitors Targeting the EGFR\/ErbB Family of Protein-Tyrosine Kinases in Human Cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of Small Molecule Protein Kinase Inhibitors Based upon the Structures of Their Drug-Enzyme Complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1021\/acs.accounts.7b00012","article-title":"Tyrosine Kinase Activation and Conformational Flexibility: Lessons from Src-Family Tyrosine Kinases","volume":"50","author":"Meng","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1126\/science.8066447","article-title":"A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase","volume":"265","author":"Fry","year":"1994","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01803785","article-title":"Specific Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase by 4-Anilinoquinazolines","volume":"38","author":"Wakeling","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Amelia, T., Kartasasmita, R.E., Ohwada, T., and Tjahjono, D.H. (2022). Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules, 27.","DOI":"10.3390\/molecules27030819"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003495-200060001-00004","article-title":"ZD1839 (\u2018Iressa\u2019) as an Anticancer Agent","volume":"60","author":"Baselga","year":"2000","journal-title":"Drugs"},{"key":"ref_75","first-page":"7184","article-title":"The Tyrosine Kinase Inhibitor ZD1839 (\u201cIressa\u201d) Inhibits HER2-Driven Signaling and Suppresses the Growth of HER2-Overexpressing Tumor Cells","volume":"61","author":"Moasser","year":"2001","journal-title":"Cancer Res."},{"key":"ref_76","first-page":"8887","article-title":"Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2\/Neu (erbB2)-Overexpressing Breast Cancer Cells In Vitro and In Vivo","volume":"61","author":"Moulder","year":"2001","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21037\/tcr.2018.12.34","article-title":"Akt\/mTOR and AMPK Signaling Pathways Are Responsible for Liver X Receptor Agonist GW3965-Enhanced Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cell Lines","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3892\/ol.2016.4606","article-title":"Gefitinib Induces Lung Cancer Cell Autophagy and Apoptosis via Blockade of the PI3K\/AKT\/mTOR Pathway","volume":"12","author":"Zhao","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_79","first-page":"3387","article-title":"Antiproliferative Effects of Gefitinib Are Associated with Suppression of E2F-1 Expression and Telomerase Activity","volume":"26","author":"Suenaga","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/ar.20938","article-title":"Gefitinib Inhibits the Proliferation of Pancreatic Cancer Cells via Cell Cycle Arrest","volume":"292","author":"Zhou","year":"2009","journal-title":"Anat. Rec."},{"key":"ref_81","first-page":"1823","article-title":"Gefitinib Suppresses Cervical Cancer Progression by Inhibiting Cell Cycle Progression and Epithelial-Mesenchymal Transition","volume":"18","author":"Zheng","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa) Tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","article-title":"EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression","volume":"10","author":"Li","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.12788\/jcso.0195","article-title":"Approval Reinstates Gefitinib as a Therapy for Lung Cancer","volume":"13","year":"2015","journal-title":"J. Community Support. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA Drug Approval Summary: Erlotinib (Tarceva) Tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.21873\/anticanres.14883","article-title":"Erlotinib Activates Different Cell Death Pathways in EGFR-Mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems","volume":"41","author":"Lee","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1002\/cam4.881","article-title":"Erlotinib Induces the Human Non-Small-Cell Lung Cancer Cells Apoptosis via Activating ROS-Dependent JNK Pathways","volume":"5","author":"Shan","year":"2016","journal-title":"Cancer Med."},{"key":"ref_89","first-page":"1547","article-title":"Influence of Gefitinib and Erlotinib on Apoptosis and C-MYC Expression in H23 Lung Cancer Cells","volume":"33","author":"Suenaga","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., and Poddubskaya, E. (2023). Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways. Cells, 12.","DOI":"10.3390\/cells12162022"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.18632\/oncotarget.6276","article-title":"Intermittent High-Dose Treatment with Erlotinib Enhances Therapeutic Efficacy in EGFR-Mutant Lung Cancer","volume":"6","author":"Chatterjee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib versus Chemotherapy as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-Line Erlotinib versus Gemcitabine\/Cisplatin in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Analyses from the Phase III, Randomized, Open-Label, ENSURE Study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as Maintenance Treatment in Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised, Placebo-Controlled Phase 3 Study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_96","first-page":"83","article-title":"Erlotinib in the Treatment of Advanced Pancreatic Cancer","volume":"2","author":"Kelley","year":"2008","journal-title":"Biologics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"587849","DOI":"10.3389\/fonc.2020.587849","article-title":"Efficacy and Tolerability of Erlotinib 100 Mg\/d vs. Gefitinib 250 Mg\/d in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/1817-1737.118503","article-title":"Erlotinib in Wild Type Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer: A Systematic Review","volume":"8","author":"Jazieh","year":"2013","journal-title":"Ann. Thorac. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., and Varmus, H. (2005). Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020073"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET Amplification Occurs with or without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationships among Protein Conformation, Inhibitor off-Rate, and Receptor Activity in Tumor Cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"012075","DOI":"10.1088\/1755-1315\/1041\/1\/012075","article-title":"In-Silico Screening of Inhibitor on Protein Epidermal Growth Factor Receptor (EGFR)","volume":"1041","author":"Ongko","year":"2022","journal-title":"IOP Conf. Ser. Earth Environ. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.clinthera.2009.11.029","article-title":"Lapatinib: A Small-Molecule Inhibitor of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Tyrosine Kinases Used in the Treatment of Breast Cancer","volume":"31","author":"Tevaarwerk","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_104","first-page":"85","article-title":"The Effects of the Novel, Reversible Epidermal Growth Factor Receptor\/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-Derived Cell Lines In Vitro and In Vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol. Cancer Ther."},{"key":"ref_105","first-page":"235","article-title":"Effects of Lapatinib on Cell Proliferation and Apoptosis in NB4 Cells","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.canlet.2008.07.018","article-title":"The Growth Inhibitory Effect of Lapatinib, a Dual Inhibitor of EGFR and HER2 Tyrosine Kinase, in Gastric Cancer Cell Lines","volume":"272","author":"Kim","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/sj.bjc.6604278","article-title":"Activity of Lapatinib a Novel HER2 and EGFR Dual Kinase Inhibitor in Human Endometrial Cancer Cells","volume":"98","author":"Konecny","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/cas.12290","article-title":"Heregulin Induces Resistance to Lapatinib-Mediated Growth Inhibition of HER2-Amplified Cancer Cells","volume":"104","author":"Sato","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/jnci\/djn216","article-title":"Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain","volume":"100","author":"Gril","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1158\/1078-0432.CCR-09-1112","article-title":"Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and Is Synergistic with Trastuzumab In Vitro and In Vivo","volume":"16","author":"Wainberg","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","article-title":"Lapatinib plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial","volume":"15","author":"Cameron","year":"2010","journal-title":"Oncologist"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib Combined with Letrozole versus Letrozole and Placebo as First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, Double-Blind, Randomized Study Comparing Lapatinib plus Paclitaxel with Placebo plus Paclitaxel as First-Line Treatment for Metastatic Breast Cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of Acquired Resistance to First- and Second-Generation EGFR Tyrosine Kinase Inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/s41401-021-00791-5","article-title":"Rational Application of Gefitinib in NSCLC Patients with Sensitive EGFR Mutations Based on Pharmacokinetics and Metabolomics","volume":"43","author":"Feng","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: First Global Approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2021.047","article-title":"Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations","volume":"30","author":"Duggirala","year":"2022","journal-title":"Biomol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an Irreversible EGFR\/HER2 Inhibitor Highly Effective in Preclinical Lung Cancer Models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11523-014-0353-6","article-title":"Afatinib Efficacy against Squamous Cell Carcinoma of the Head and Neck Cell Lines In Vitro and In Vivo","volume":"10","author":"Young","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/DDDT.S94432","article-title":"In Vitro and In Vivo Efficacy of Afatinib as a Single Agent or in Combination with Gemcitabine for The&nbsp;Treatment of Nasopharyngeal Carcinoma","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_123","first-page":"2005","article-title":"Afatinib Is Especially Effective against Non-Small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion","volume":"35","author":"Banno","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","article-title":"A Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients with HER2-Positive Metastatic Breast Cancer Progressing after Trastuzumab","volume":"133","author":"Lin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mds284","article-title":"Safety and Efficacy of Neratinib (HKI-272) plus Vinorelbine in the Treatment of Patients with ErbB2-Positive Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy","volume":"24","author":"Awada","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ardp.200800009","article-title":"The Development of HKI-272 and Related Compounds for the Treatment of Cancer","volume":"341","author":"Wissner","year":"2008","journal-title":"Arch. Pharm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41416-020-01257-x","article-title":"Comparative Analysis of Drug Response and Gene Profiling of HER2-Targeted Tyrosine Kinase Inhibitors","volume":"124","author":"Conlon","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/jco.2015.33.15_suppl.1099","article-title":"Neratinib to Inhibit the Growth of Triple-Negative Breast Cancer Cells","volume":"33","author":"Mullooly","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/ddr.21983","article-title":"Neratinib Inhibits Proliferation and Promotes Apoptosis of Acute Myeloid Leukemia Cells by Activating Autophagy-Dependent Ferroptosis","volume":"83","author":"Ma","year":"2022","journal-title":"Drug Dev. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib Overcomes Trastuzumab Resistance in HER2 Amplified Breast Cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced ErbB2-Positive Breast Cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.2014.56.3809","article-title":"Safety and Efficacy of Neratinib in Combination with Capecitabine in Patients with Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer","volume":"32","author":"Saura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","article-title":"U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer","volume":"24","author":"Singh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2023.02.002","article-title":"Overall Survival with Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"184","author":"Holmes","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated with \u22652 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"646","DOI":"10.5306\/wjco.v5.i4.646","article-title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer","volume":"5","author":"Asami","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1358\/dot.2019.55.4.2965337","article-title":"Dacomitinib, a Second-Generation Irreversible Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) to Treat Non-Small Cell Lung Cancer","volume":"55","author":"Nagano","year":"2019","journal-title":"Drugs Today"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/092986711796391705","article-title":"Irreversible Protein Kinase Inhibitors","volume":"18","author":"Garuti","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations That Are Resistant to Gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","article-title":"Antitumor Activity and Pharmacokinetic Properties of PF-00299804, a Second-Generation Irreversible Pan-erbB Receptor Tyrosine Kinase Inhibitor","volume":"7","author":"Gonzales","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Williams, J.P., Kim, I., Ito, E., Shi, W., Yue, S., Siu, L.L., Waldron, J., O\u2019Sullivan, B., Yip, K.W., and Liu, F.-F. (2014). Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098557"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2119\/molmed.2013.00108","article-title":"Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer","volume":"19","author":"Grivas","year":"2013","journal-title":"Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): A Randomised, Open-Label, Phase 3 Trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/1759-7714.14415","article-title":"Clinical Efficacy of Dacomitinib in Rechallenge Setting for Patients with Epidermal Growth Factor Receptor Mutant Non\u2013Small Cell Lung Cancer: A Multicenter Retrospective Analysis ( TOPGAN2020-02)","volume":"13","author":"Tanaka","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Zhang, B., Shi, C., Gao, Z., Zhong, H., Xiong, L., Gu, A., Wang, W., Chu, T., Zhang, W., and Wang, H. (2022). Rationale and Design of a Phase II Trial of Dacomitinib in Advanced Non-Small Cell Lung Cancer Patients with Uncommon Epidermal Growth Factor Receptor Mutations: A Prospective and Single Arm Study (DANCE Study). BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09409-3"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/1078-0432.CCR-12-2353","article-title":"Vandetanib for the Treatment of Medullary Thyroid Cancer","volume":"19","author":"Chau","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_151","unstructured":"(2023, November 24). CAPRELSA\u00ae (Vandetanib) Tablets, for Oral Use Ab\u03d5\u2014\u220fo\u0438ck b Google. Available online: https:\/\/www.google.com\/search?q=CAPRELSA%C2%AE+%28vandetanib%29+tablets%2C+for+oral+use+%D0%B0%D0%B2%D1%84&newwindow=1&client=safari&sca_esv=585026838&rls=en&ei=YYJgZYT7ONOXjgb3hrmgCw&ved=0ahUKEwjEr-vrvdyCAxXTi8MKHXdDDrQQ4dUDCA8&uact=5&oq=CAPRELSA%C2%AE+%28vandetanib%29+tablets%2C+for+oral+use+%D0%B0%D0%B2%D1%84&gs_lp=Egxnd3Mtd2l6LXNlcnAiNENBUFJFTFNBwq4gKHZhbmRldGFuaWIpIHRhYmxldHMsIGZvciBvcmFsIHVzZSDQsNCy0YQyCBAAGIAEGKIEMggQABiABBiiBEizDFArWLYLcAF4AZABAJgBkAGgAaIDqgEDMi4yuAEDyAEA-AEBwgIKEAAYRxjWBBiwA-IDBBgAIEGIBgGQBgU&sclient=gws-wiz-serp."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbrc.2020.07.111","article-title":"Vandetanib Inhibits Cell Growth in EGFR-Expressing Cutaneous Squamous Cell Carcinoma","volume":"531","author":"Kitamura","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1158\/0008-5472.CAN-08-4204","article-title":"Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In Vivo","volume":"69","author":"Ichihara","year":"2009","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib Versus Placebo in Patients with Advanced Non-Small-Cell Lung Cancer after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/DDDT.S147499","article-title":"Brigatinib for ALK-Positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy","volume":"13","author":"Ali","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_156","unstructured":"Food and Drug Administration (2021). FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and Safety of Brigatinib in ALK-Rearranged Non-Small-Cell Lung Cancer and Other Malignancies: A Single-Arm, Open-Label, Phase 1\/2 Trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","article-title":"Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay","volume":"17","author":"Arcila","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and Other Third-Generation EGFR TKI in EGFR-Mutant NSCLC Patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bmcl.2016.02.067","article-title":"Recent Progress on Third Generation Covalent EGFR Inhibitors","volume":"26","author":"Cheng","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-Mutated Advanced NSCLC: A Multicenter, Open-Label, Phase 1 Trial","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1177\/09603271211030554","article-title":"EGFR Tyrosine Kinase Inhibitor Almonertinib Induces Apoptosis and Autophagy Mediated by Reactive Oxygen Species in Non-Small Cell Lung Cancer Cells","volume":"40","author":"Ge","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jtho.2019.08.413","article-title":"OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI","volume":"14","author":"Lu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer with EGFR Exon 19 Deletion or L858R Mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","article-title":"YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer","volume":"25","author":"Yun","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/cas.15263","article-title":"Utility of the Ba\/F3 Cell System for Exploring on-Target Mechanisms of Resistance to Targeted Therapies for Lung Cancer","volume":"113","author":"Koga","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Results from the Dose Escalation and Dose Expansion Parts of a First-in-Human, Open-Label, Multicentre, Phase 1\u20132 Study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_174","first-page":"67","article-title":"Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (Del19, L858R, T790M, Exon 20 Insertions, \u201cUncommon-G719X, S768I, L861Q\u201d) Among the Third-Generation EGFR TKIs?","volume":"13","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41401-020-0389-3","article-title":"Alflutinib (AST2818), Primarily Metabolized by CYP3A4, Is a Potent CYP3A4 Inducer","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients with Advanced NSCLC with EGFR T790M Mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus Gefitinib as First-Line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer (FURLONG): A Multicentre, Double-Blind, Randomised Phase 3 Study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_178","unstructured":"ArriVent BioPharma, Inc (2023, November 17). Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)\u2014Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05607550."},{"key":"ref_179","first-page":"100105","article-title":"Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations","volume":"2","author":"Vasconcelos","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/OTT.S374489","article-title":"Clinical Utility of Mobocertinib in the Treatment of NSCLC\u2014Patient Selection and Reported Outcomes","volume":"16","author":"Arnold","year":"2023","journal-title":"OncoTargets Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1538-7445.AM2016-2644","article-title":"Abstract 2644: AP32788, a Potent, Selective Inhibitor of EGFR and HER2 Oncogenic Mutants, Including Exon 20 Insertions, in Preclinical Models","volume":"76","author":"Gonzalvez","year":"2016","journal-title":"Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1\/2 Open-Label Nonrandomized Clinical Trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_183","first-page":"100462","article-title":"The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations","volume":"4","author":"Kagawa","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_184","first-page":"61","article-title":"Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations","volume":"12","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_185","unstructured":"(2023, November 16). FDA and Takeda to Withdraw Mobocertinib for EGFR Exon20+ NSCLC. Available online: https:\/\/www.targetedonc.com\/view\/fda-and-takeda-to-withdraw-mobocertinib-for-egfr-exon20-nsclc."},{"key":"ref_186","first-page":"593","article-title":"Lactobacillus Metabolites Relieves the Rash and Diarrhea Induced by Egfr Tki: Two Case Reports and Literature Review","volume":"54","author":"Chen","year":"2023","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_187","first-page":"1","article-title":"Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated with Osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"Cardio Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System","volume":"10","author":"Huang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management","volume":"8","author":"Sharma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"602762","DOI":"10.3389\/fonc.2020.602762","article-title":"Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.064","article-title":"Analysis of Resistance Mechanisms to Osimertinib in Patients with EGFR T790M Advanced NSCLC from the AURA3 Study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"103454","DOI":"10.1016\/j.critrevonc.2021.103454","article-title":"Hype or Hope\u2014Can Combination Therapies with Third-Generation EGFR-TKIs Help Overcome Acquired Resistance and Improve Outcomes in EGFR-Mutant Advanced\/Metastatic NSCLC?","volume":"166","author":"Papini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.bbrc.2018.05.154","article-title":"Crystal Structure of EGFR T790M\/C797S\/V948R in Complex with EAI045","volume":"502","author":"Zhao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19\/T790M\/C797S Mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"TPS9156","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9156","article-title":"A Phase 1\/2 Study of BLU-945 in Patients with Common Activating EGFR-Mutant Non\u2013Small Cell Lung Cancer (NSCLC): SYMPHONY Trial in Progress","volume":"40","author":"Shum","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2023.41.16_suppl.9011","article-title":"BLU-945 Monotherapy and in Combination with Osimertinib (OSI) in Previously Treated Patients with Advanced EGFR-Mutant (EGFRm) NSCLC in the Phase 1\/2 SYMPHONY Study","volume":"41","author":"Elamin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/1538-7445.AM2021-1262","article-title":"Abstract 1262: BLU-701 Is a Highly Potent, Brain-Penetrant and WT-Sparing next-Generation EGFR TKI for the Treatment of Sensitizing (Ex19del, L858R) and C797S Resistance Mutations in Metastatic NSCLC","volume":"81","author":"Conti","year":"2021","journal-title":"Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/1538-7445.AM2022-3328","article-title":"Abstract 3328: Antitumor Activity of BLU-945 and BLU-701 as Single Agents and in Combination in EGFR L858R-Driven Models of NSCLC","volume":"82","author":"Tavera","year":"2022","journal-title":"Cancer Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"TPS9142","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9142","article-title":"A Phase 1\/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non\u2013Small Cell Lung Cancer (NSCLC)","volume":"40","author":"Spira","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jtho.2022.07.117","article-title":"MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC","volume":"17","author":"Yun","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1039\/D3RA02347H","article-title":"Insights into Fourth Generation Selective Inhibitors of (C797S) EGFR Mutation Combating Non-Small Cell Lung Cancer Resistance: A Critical Review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","article-title":"Growth Stimulation of A431 Cells by Epidermal Growth Factor: Identification of High-Affinity Receptors for Epidermal Growth Factor by an Anti-Receptor Monoclonal Antibody","volume":"80","author":"Kawamoto","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for Combination of Therapeutic Antibodies Targeting Tumor Cells and Immune Checkpoint Receptors: Harnessing Innate and Adaptive Immunity through IgG1 Isotype Immune Effector Stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-Based Treatment of HER2-Positive Breast Cancer: An Antibody-Dependent Cellular Cytotoxicity Mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1349-7006.2007.00510.x","article-title":"Antibody-Dependent Cellular Cytotoxicity of Cetuximab against Tumor Cells with Wild-Type or Mutant Epidermal Growth Factor Receptor","volume":"98","author":"Kimura","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/sj.onc.1210381","article-title":"Cetuximab, a Chimeric Human Mouse Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in the Treatment of Human Colorectal Cancer","volume":"26","author":"Galizia","year":"2007","journal-title":"Oncogene"},{"key":"ref_213","first-page":"1311","article-title":"Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model","volume":"1","author":"Goldstein","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural Basis for Inhibition of the Epidermal Growth Factor Receptor by Cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1006302101468","article-title":"Role of an Anti-Epidermal Growth Factor Receptor in Treating Cancer","volume":"18","author":"Waksal","year":"1999","journal-title":"Cancer Metastasis Rev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","article-title":"Differential Effects of Gefitinib and Cetuximab on Non-Small-Cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations","volume":"97","author":"Mukohara","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10120-011-0102-9","article-title":"In Vitro and In Vivo Antitumor Activity of Cetuximab in Human Gastric Cancer Cell Lines in Relation to Epidermal Growth Factor Receptor (EGFR) Expression and Mutational Phenotype","volume":"15","author":"Hotz","year":"2012","journal-title":"Gastric Cancer"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00280-005-0123-3","article-title":"In Vivo and In Vitro Antitumor Activity of Oxaliplatin in Combination with Cetuximab in Human Colorectal Tumor Cell Lines Expressing Different Level of EGFR","volume":"57","author":"Delord","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000065726","article-title":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Upregulates P27KIP1 and P15INK4B and Induces G1 Arrest in Oral Squamous Carcinoma Cell Lines","volume":"63","author":"Kiyota","year":"2002","journal-title":"Oncology"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41598-021-84877-4","article-title":"Prolonged Cetuximab Treatment Promotes p27Kip1-Mediated G1 Arrest and Autophagy in Head and Neck Squamous Cell Carcinoma","volume":"11","author":"Okuyama","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1515\/tjb-2018-0033","article-title":"Enhanced Anticancer Effect of Cetuximab Combined with Stabilized Silver Ion Solution in EGFR-Positive Lung Cancer Cells","volume":"44","author":"Ozkan","year":"2019","journal-title":"Turk. J. Biochem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e06394","DOI":"10.1016\/j.heliyon.2021.e06394","article-title":"Human Blood Serum Can Donor-Specifically Antagonize Effects of EGFR-Targeted Drugs on Squamous Carcinoma Cell Growth","volume":"7","author":"Kamashev","year":"2021","journal-title":"Heliyon"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Kamashev, D., Shaban, N., Suntsova, M., Raevskiy, M., Efimov, V., Moisseev, A., Sorokin, M., and Buzdin, A. (2022). Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081914"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II Trial of Cetuximab in Patients with Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: Phase III Trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","article-title":"Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial","volume":"36","author":"Qin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.06.039","article-title":"First-Line Treatment with Chemotherapy plus Cetuximab in Chinese Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety Results of the Randomised, Phase III CHANGE-2 Trial","volume":"156","author":"Guo","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_229","unstructured":"(2023, November 17). Information on Cetuximab (Marketed as Erbitux)|FDA, Available online: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-cetuximab-marketed-erbitux."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","article-title":"Cetuximab: A Review of Its Use in Squamous Cell Carcinoma of the Head and Neck and Metastatic Colorectal Cancer","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/PPO.0b013e31819e3202","article-title":"KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer","volume":"15","author":"Jimeno","year":"2009","journal-title":"Cancer J."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1593\/neo.121242","article-title":"Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab","volume":"14","author":"Voigt","year":"2012","journal-title":"Neoplasia"},{"key":"ref_234","first-page":"223","article-title":"Targeting Colorectal Cancer with Human Anti-EGFR Monoclonocal Antibodies: Focus on Panitumumab","volume":"2","author":"Kim","year":"2008","journal-title":"Biologics"},{"key":"ref_235","first-page":"1236","article-title":"Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy","volume":"59","author":"Yang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a Fully Human Anti-EGF Receptor Monoclonal Antibody, for Cancer Therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer","volume":"25","author":"Peeters","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.2147\/CMAR.S186042","article-title":"The Impact of Panitumumab Treatment on Survival and Quality of Life in Patients with RAS Wild-Type Metastatic Colorectal Cancer","volume":"11","author":"Battaglin","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_240","first-page":"119","article-title":"Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer","volume":"9","author":"Fala","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"19665","DOI":"10.1074\/jbc.M500815200","article-title":"A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity","volume":"280","author":"Lu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-09-2425","article-title":"A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies","volume":"16","author":"Kuenen","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_243","first-page":"77","article-title":"Preclinical Rationale for Combining an EGFR Antibody with Cisplatin\/Gemcitabine for the Treatment of NSCLC","volume":"9","author":"Samakoglu","year":"2012","journal-title":"Cancer Genom. Proteom."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin Alone as First-Line Therapy in Patients with Stage IV Squamous Non-Small-Cell Lung Cancer (SQUIRE): An Open-Label, Randomised, Controlled Phase 3 Trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14712598.2018.1508445","article-title":"Necitumumab in the Treatment of Non-Small-Cell Lung Cancer: Clinical Controversies","volume":"18","author":"Pilotto","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CCO.0000000000000260","article-title":"Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer","volume":"28","author":"Pirker","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fonc.2020.00447","article-title":"Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-0716-0138-9_17","article-title":"Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data","volume":"2063","author":"Tkachev","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Sorokin, M., Zolotovskaia, M., Nikitin, D., Suntsova, M., Poddubskaya, E., Glusker, A., Garazha, A., Moisseev, A., Li, X., and Sekacheva, M. (2022). Personalized Targeted Therapy Prescription in Colorectal Cancer Using Algorithmic Analysis of RNA Sequencing Data. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10177-3"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/hgv.2015.9","article-title":"Pathway Activation Strength Is a Novel Independent Prognostic Biomarker for Cetuximab Sensitivity in Colorectal Cancer Patients","volume":"2","author":"Zhu","year":"2015","journal-title":"Hum. Genome Var."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/1\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:41:55Z","timestamp":1760132515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/1\/47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":251,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cells13010047"],"URL":"https:\/\/doi.org\/10.3390\/cells13010047","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]}}}